Skip to main content
Terminated

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

By April 24, 2017No Comments

Condition

Epithelioid Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatoid Mesothelioma|Stage II Pleural Mesothelioma|Stage III Pleural Mesothelioma|Stage IV Pleural Mesothelioma

Estimated Enrollment: 18

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: NCI-2013-00937|12-2158|9267|N01CM00071|P30CA014599

Study First Received: May 20, 2013

Last Updated: August 26, 2016

Estimated Primary Completion Date: March 2015

 

Primary Outcome Measures:

Objective Radiologic Response Rate (Complete or Partial Response) Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1|Incidence of Adverse Events, Graded Per NCI CTCAE Version 4|Overall Survival|Progression-free Survival

Sponsors and Collaborators:

National Cancer Institute (NCI)

Website Link: https://ClinicalTrials.gov/show/NCT01861301

Leave a Reply